CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D009206: Myocard NIH

(Synonyms: Myo, Myoc, Myoca, Myocar, Myocard, Myocardi, Myocardia, Myocardial, Myocardial )

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D007238 Infarction NIH 0.38
D009203 Myocardial Ischemia NIH 0.29

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001658 Myocardial infarction HPO 0.29

There is one clinical trial.

Clinical Trials


1 Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study

In late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.

NCT04357314 Myocardial Infarction
MeSH:Myocard Myocardial Infarction Infarction
HPO:Myocardial infarction

Primary Outcomes

Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020

Measure: Rates of patients presenting with acute myocardial infarction

Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )

Secondary Outcomes

Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19

Measure: Patient profile during admission for acute myocardial infarction

Time: 3 months (between March 1 to May 31

Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19

Measure: Medical care times analysis

Time: 3 months (between March 1 to May 31)

Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19

Measure: Proportion of patients who underwent systemic thrombolysis

Time: 3 months (between March 1 to May 31)

Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19

Measure: Proportion of patients infected with COVID-19

Time: 3 months (between March 1 to May 31)

Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at discharge

Measure: Clinical evolution of patients

Time: 3 months (between March 1 to May 31)


HPO Nodes